Skip to content

A Study of remimazolam compared with propofol in the treatment of patients with esophageal varices under gastroscopy

A Study of remimazolam compared with propofol in the treatment of patients with esophageal varices under gastroscopy

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100042044
Enrollment
Unknown
Registered
2021-01-12
Start date
2021-01-15
Completion date
Unknown
Last updated
2021-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroscopic anesthesia for esophageal varices

Interventions

Sponsors

the First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with esophageal varices who plan to undergo painless gastroscopy treatment; 2. Age over 18 years old, no gender limit; 3. ASA score is I-III grade; 4. Before the test, understand the nature, significance, possible benefits, possible inconveniences and potential dangers of the test in detail, understand the research procedures and voluntarily sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. Those who are allergic to benzodiazepines, flumazenil, opioids, naloxone, propofol, soybeans, and peanuts; 2. Long-term use or abuse of benzodiazepines and opioids; 3. Patients with myasthenia gravis, schizophrenia, severe depression; 4. People with a history of drug or alcohol abuse in the past two years; 5. Patients with hypotension or shock; 6. Patients under 16 years old; 7. Pregnant women and lactating patients; 8. Those who have a history of abnormal surgical anesthesia recovery; 9. Those who have participated in clinical trials related to remazolam tosylate in the past; 10. Those who are unable to effectively communicate with the researcher or are deemed inappropriate by the researcher.

Design outcomes

Primary

MeasureTime frame
Wake up time;

Secondary

MeasureTime frame
Sedation success rate;Adverse event rate;Incidence of injection pain;Intraoperative awareness rate;

Countries

China

Contacts

Public ContactWang xiuhong
405440892@qq.com+86 15979166716

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026